Jodie Sherman Gillon

Jodie Gillon serves as the VP Patient Advocacy & Clinical Affairs at Abeona Therapeutics a cell and gene therapy company. In this role she serves as the main point of contact for Advocacy groups, patients and families as well as oversees Medical Communications & Information, Contributions, Congresses/Meetings, Medical Education, Grants and Contributions. Jodie started her career in Advocacy, Hospitals and Government and transitioned to industry over two decades ago holding various roles across Development, Medical & Corporate Affairs.  Prior to joining Abeona, Jodie cumulatively spent over a decade with Pfizer as the Global Medical Lead, Patient Engagement, for the Rare Diseases Business Unit and the Director, Medical Communications, within the Chief Medical Office. She served as a core member on all Medical, Commercial, Launch, Global and Regional Leadership Teams ensuring the patient voice drove strategy and facilitated collaborations with Patient Groups.

Prior to Pfizer, Jodie was the Head of Patient Advocacy and Professional Affairs with Achillion Pharmaceuticals where she led Policy, Alliances, Patient Engagement, Contributions/Grants, Compassionate Use, Medical Information, Medical Communications, Field Medical, and External Affairs. Previously she served as the Head of the Chief Medical Office (CMO) of AstraZeneca where she managed Patient Engagement, Compassionate Use, Trial and Payment Transparency, Meetings and Events, an HCP Engagement Center, companywide policy, external contributions, alliances, and crisis management.

Jodie held additional roles as the Global Communications lead at Novartis, Director of Medical Education for Oridion Medical and as a Health Economist with the Israeli Center for Disease Control and Ministry of Health.  She holds a Master’s of Public Health with a dual degree in Health Economics and Epidemiology from Hebrew University in Jerusalem and a BSFS from Georgetown’s School of Foreign Service. She currently serves on several industrywide Boards pertaining to Patient Advocacy, Rare Diseases, Compassionate Use, Innovation and Artificial Intelligence.